The safety of in-hospital initiation of SGLT2 inhibitor with MRA therapy in patients hospitalized for heart failure with a reduced left ventricular ejection fraction and chronic kidney disease

dc.contributor.author	Obertynska, O.	en
dc.contributor.author	Rasputina, L.	en
dc.date.accessioned	2025-03-13T11:46:29Z
dc.date.available	2025-03-13T11:46:29Z
dc.date.issued	2024
dc.identifier.citation	Obertynska O. The safety of in-hospital initiation of SGLT2 inhibitor with MRA therapy in patients hospitalized for heart failure with a reduced left ventricular ejection fraction and chronic kidney disease / O. Obertynska, L. Rasputina // European Heart Journal. – 2024. – Vol. 45, № 1.	en
dc.identifier.other	DOI: 10.1093/eurheartj/ehae666.1055
dc.identifier.uri	https://dspace.vnmu.edu.ua/123456789/7530	en
dc.description.abstract	Deferring in-hospital initiation of guideline-recommended medications in HFrEF has a few chances they will be initiated ambulatory, especially in the case of coexisting HFrEF and chronic kidney disease (CKD). The aim was to investigate the safety of in-hospital initiation of SGLT2i with MRA therapy for patients hospitalized for HFrEF and CKD 3.	en
dc.language.iso	en	en
dc.publisher	European Heart Journal	en
dc.subject	heart failure	en
dc.subject	SGLT2 inhibitor	en
dc.subject	chronic kidney disease	en
dc.title	The safety of in-hospital initiation of SGLT2 inhibitor with MRA therapy in patients hospitalized for heart failure with a reduced left ventricular ejection fraction and chronic kidney disease	en
dc.type	Thesis	en